Skip to main content

Phenomix Inks Deal with Genentech

NEW YORK, July 12 (GenomeWeb News) - Phenomix said today that it has signed a deal to help Genentech identify and prioritize drug targets for the treatment of immune disorders.

 

Under the terms of the multi-year deal, Phenomix will use its forward genetics technology to identify new disease targets in immunology. Genentech will have the exclusive global rights to develop therapeutics using the targets, while Phenomix retains the rights to develop undisclosed products based on certain targets.

 

Phenomix said it will receive an upfront fee and an equity investment from Genentech, as well as research funding and milestones. Additional terms were not disclosed.

 

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.